Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study
ConditionParkinson's Disease
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMedtronicNeuro
About this trial
The purpose of the study is to evaluate the effectiveness of the Medtronic Adaptive DBS therapy (aDBS) for Parkinson's Disease in China with the Percept family of Implantable Neurostimulators (Percept PC and Percept RC).
Eligibility criteria
Qualifiers
Subjects must meet all general inclusion/
Disqualifiers
Subjects must meet the LFP screening inclusion criterion (as assessed at the LFP Screening Visit)
Subject has idiopathic Parkinson's disease
Subject is implanted (>3 months prior to enrollment for new INS implants or >1 month from INS replacement) with a Percept PC (Model B35200) or Percept RC (Model B35300) and Medtronic DBS leads (Model 3387, 3389, B33005 or B33015) and extensions (Model 37086 or B34000) bilaterally in the same target (physician confirmed), STN or GPi
In the opinion of the investigator, the subject responds to DBS Therapy.
Trial design
Treatments tested in this trial
- Percept™ PC and Percept RC with Adaptive DBS (aDBS™)
Treatment groups
62 Participants
are divided into 1 treatment groupLocations
5Xuanwu Hospital BeijingBeijing Municipality, China
Sun Yat-sen Hospital GuangzhouGuangdong, China
Huashan Hospital ShanghaiShanghai Municipality, China
Ruijin Hospital ShanghaiShanghai Municipality, China
Sponsors and collaborators
MedtronicNeuro
Lead sponsor
Source ClinicalTrials.gov